We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+6.2%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.34B
AUM Growth
+$16.6M
Cap. Flow
+$14.4M
Cap. Flow %
0.61%
Top 10 Hldgs %
72.44%
Holding
37
New
–
Increased
22
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$32.3M
2
INSM icon
Insmed
INSM
+$19.9M
3
SHPG
Shire pic
SHPG
+$7.63M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.39M
5
CELG
Celgene Corp
CELG
+$6.84M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$60.5M
2
BIVV
Bioverativ Inc. Common Stock
BIVV
+$14.3M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 92.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$392M 16.76%
1,346,660
-238,753
-15% -$60.5M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$209M 8.93%
3,955,660
+552,879
+16% +$32.3M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$13.3B
$206M 8.82%
2,545,482
+47,676
+2% +$4.09M
UTHR icon
4
United Therapeutics
UTHR
$22.7B
$182M 7.8%
1,622,631
+16,381
+1% +$2.08M
INSM icon
5
Insmed
INSM
$29.4B
$161M 6.89%
7,159,590
+755,004
+12% +$19.9M
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$132M 5.64%
818,331
+7,525
+0.9% +$1.28M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$127M 5.41%
1,135,845
+18,203
+2% +$2.18M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$122M 5.23%
6,895,075
+34,232
+0.5% +$578K
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$92.5M 3.95%
6,147,829
+141,807
+2% +$2.16M
IMMU
10
DELISTED
Immunomedics Inc
IMMU
$70.1M 3%
4,796,008
+21,747
+0.5% +$355K
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$304M
$70M 2.99%
4,155,670
– –
AMAG
12
DELISTED
AMAG Pharmaceuticals
AMAG
$67.3M 2.88%
3,340,806
-152,414
-4% -$2.58M
ALGN icon
13
Align Technology
ALGN
$12.5B
$54.9M 2.35%
218,707
+6,200
+3% +$1.59M
WMGI
14
DELISTED
Wright Medical Group Inc
WMGI
$54.6M 2.34%
2,752,294
+16,001
+0.6% +$343K
STAA icon
15
STAAR Surgical
STAA
$1.25B
$52M 2.22%
3,515,385
+18,633
+0.5% +$291K
KPTI icon
16
Karyopharm Therapeutics
KPTI
$44.4M
$49.4M 2.11%
245,332
+9,036
+4% +$1.8M
AIMT
17
DELISTED
Aimmune Therapeutics
AIMT
$43.2M 1.85%
1,356,514
+210,095
+18% +$7.39M
PRTA icon
18
Prothena Corp
PRTA
$468M
$40.4M 1.73%
1,101,338
+5,683
+0.5% +$207K
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$5.06B
$37.1M 1.59%
1,650,780
+9,750
+0.6% +$270K
CELG
20
DELISTED
Celgene Corp
CELG
$33.8M 1.45%
379,140
+71,200
+23% +$6.84M
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$33.2M 1.42%
1,830,435
+8,859
+0.5% +$148K
SHPG
22
DELISTED
Shire pic
SHPG
$28.6M 1.22%
191,200
+55,400
+41% +$7.63M
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
$23.5M 1%
1,849,832
+9,586
+0.5% +$139K
RIGL icon
24
Rigel Pharmaceuticals
RIGL
$778M
$14M 0.6%
396,609
+3,051
+0.8% +$122K
GILD icon
25
Gilead Sciences
GILD
$165B
$13.3M 0.57%
175,900
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q1 2018 Portfolio in Review

As of Q1 2018, Palo Alto Investors held 37 positions worth $2.34B, up 0.71% from $2.32B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Trading was light in Q1 2018: portfolio turnover was 2.7%. Palo Alto Investors opened no new positions and exited 1, leaving the 37-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q1 2018, an estimated $32.3M increase.
  • Palo Alto Investors's biggest Q1 2018 reduction was Abiomed Inc, cutting an estimated $60.5M.
  • Palo Alto Investors fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $14.3M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $2.34B portfolio in Q1 2018.
  • Palo Alto Investors opened 0 new positions and closed 1 in Q1 2018.
  • Palo Alto Investors's portfolio value rose 0.71% quarter-over-quarter to $2.34B.

Based on Palo Alto Investors's 13F filing for Q1 2018, filed 15 May 2018.